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Background: Besides its growing importance in clinical diagnostics and understanding the genetic basis of
Mendelian and complex diseases, whole exome sequencing (WES) is a rich source of additional information of
potential clinical utility for physicians, patients and their families. We analyzed the frequency and nature of single
nucleotide variants (SNVs) considered secondary findings and recessive disease allele carrier status in the exomes of
8554 individuals from a large, randomly sampled cohort study and 2514 patients from a study of presumed
Mendelian disease having undergone WES.
Methods: We used the same sequencing platform and data processing pipeline to analyze all samples and
characterized the distributions of reported pathogenic (ClinVar, Human Gene Mutation Database (HGMD)) and
predicted deleterious variants in the pre-specified American College of Medical Genetics and Genomics (ACMG)
secondary findings and recessive disease genes in different ethnic groups.
Results: In the 56 ACMG secondary findings genes, the average number of predicted deleterious variants per
individual was 0.74, and the mean number of ClinVar reported pathogenic variants was 0.06. We observed an
average of 10 deleterious and 0.78 ClinVar reported pathogenic variants per individual in 1423 autosomal recessive
disease genes. By repeatedly sampling pairs of exomes, 0.5 % of the randomly generated couples were at 25 % risk
of having an affected offspring for an autosomal recessive disorder based on the ClinVar variants.
Conclusions: By investigating reported pathogenic and novel, predicted deleterious variants we estimated the lower
and upper limits of the population fraction for which exome sequencing may reveal additional medically relevant
information. We suggest that the observed wide range for the lower and upper limits of these frequency numbers
will be gradually reduced due to improvement in classification databases and prediction algorithms.Background
Exome and genome sequencing is becoming an integral
part of health care. Their role as molecular diagnostic
tools in obstetrics [1] and pediatrics [2] is firmly estab-
lished, as is their potential in hereditary cancer [3] and
somatic testing [4]. Less well touted, but likely of
broader application, is the use of sequencing in carrier
testing for recessive disorders, as a subclinical marker of
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high risk individuals for a number of common chronic
diseases. Like any test or procedure, DNA sequencing is
able to detect findings for conditions other than the pri-
mary reason for which the original test was performed.
These findings can be broadly divided into two groups.
First, so-called secondary findings (SFs) [6, 7], i.e., vari-
ants in genes not directly related to the primary clinical
diagnosis but actively screened due to their clinical im-
portance, can have a direct impact on the health of the
ascertained individual or family members with the same
genotype. Second, sequence analysis can identify hetero-
zygous alleles that have no obvious clinical manifestation
in the carrier state but may impact future generations
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focus on individuals highly ascertained on specific phe-
notypes and studies of relatively small sample sizes.
Based on available data, it is expected that one to two
percent of individuals will have at least one of the well-
studied pathogenic variants originally identified in the
American College of Medical Genetics and Genomics
(ACMG) guidelines [8]. For example, Dorschner et al. [9]
report the frequency of actionable pathogenic variants in
114 genes to be 3.4 % in European-descent and 1.2 % in
African-descent individuals ascertained to be part of mul-
tiple case–control studies. To our knowledge no study has
reported the rates of SFs in a large (e.g., >1,000 individuals)
sample of individuals randomly selected from the US
population. Further, the distortion of SF frequencies in re-
gions populated with individuals with different specific
continental origins is largely unexplored.
We identified both SFs and recessive carrier alleles in
a large random sample of African-Americans (AAs;
N = 2836) and European-Americans (EAs; N = 5718)
from the US population. We also ascertained European
(N = 1455), African (N = 122) Turkish (N = 498), Hispanic
(N = 388) and Asian (N = 51) samples that were part of
systematic studies to discover novel Mendelian disease
genes. We utilized the same platform and algorithms for
all samples analyzed in this study, and were therefore
able to compare the rates in the AA/EA populations with
those in the other groups. By including information from
multiple data sources ranging from the widely agreed
upon and adjudicated variants in ClinVar [10] to pre-
dicted deleterious variants using dbNSFP [11], we were
able to establish the lower and upper bounds, respect-
ively, of both the SFs and recessive carrier alleles in di-
verse populations. The data presented here enable
assessment of the impact of a comprehensive carrier test-
ing program for established recessive disorders, keeping
in mind the ever-changing nature of the reference data-
bases, such as ClinVar and dbNSFP.
Methods
This research conforms to the Helsinki Declaration and
was approved by local institutional review boards. All
study participants provided written informed consent
and agreed to participate in genetic studies. Genetic
studies in the Atherosclerosis Risk in Communities
(ARIC) study have been approved by the Institutional
Review Board at the University of Texas Health Science
Center at Houston. Genetic studies in the Baylor-Johns
Hopkins Center for Mendelian Genomics (CMG) have
been approved by the Institutional Review Board at the
Baylor College of Medicine at Houston. The data are
available from dbGAP under the following accession
numbers: ARIC phs000668.v1.p1, and Baylor Hopkins
Center for Mendelian Genomics (CMG) phs000711.v2.p1.Cohorts
Whole exome sequencing was performed on 8554
individuals derived from the Atherosclerosis Risk in
Communities study [12] (ARIC) and from 2514 patients
sequenced at the CMG at Baylor College of Medicine
[13]. As part of ongoing efforts to identify genes influen-
cing risk of common heart, lung and blood diseases, we
are performing exome sequencing on members of the
ARIC study. A total of 15,792 individuals, predominantly
EA and AA, participated in the ARIC study baseline
examination in 1987–1989, with three additional trien-
nial follow-up examinations and a fifth exam in 2011–
2013. The ARIC cohort includes a sample of individuals
aged 45–64 years randomly selected and recruited from
four US communities: suburban Minneapolis, MN;
Washington County, MD; Forsyth County, NC; and
Jackson, MS [12]. All individuals whose data are in-
cluded here provided written informed consent for
large-scale genomic studies and broad data sharing.
Ethnic classification of the ARIC study sample was con-
firmed with principal components analysis performed
using the EIGENSTRAT software [14].
The primary goal of the CMG is to identify novel
genes responsible for Mendelian conditions [13]. CMG
study participants are heterogeneous in terms of
phenotypic presentation and ethnic origins. The total
number of distinct Mendelian conditions representing
clinical diagnoses included in this sample set was
250 (Additional file 1). Samples were collected from
23 countries from North and South Americas, Europe,
Asia and Australia. To obtain unbiased ethnic classifica-
tion of the CMG study participants, we used PRIMUS
[15] and genotype data from Illumina’s Human Exome
(v.1-1 or v.1-2) arrays. PRIMUS encapsulates the up-
stream quality control (QC) required before principal
components analysis and uses a clustering algorithm
to assign ancestral groups to the samples using prin-
cipal components derived from the EIGENSTRAT
software [14].
Sequencing and QC
DNA samples were processed according to protocols
previously described [16]. Sequencing was performed
using Illumina Hi-Seq (San Diego, CA) instruments after
exome capture with the Baylor Human Genome Sequen-
cing Center VCRome 2.1 (ARIC samples) or CORE [17]
(CMG samples) designs. To minimize the influence of
differences between the two designs on the results of the
comparative analysis, we identified the intersection of
the capture designs and excluded variants located out-
side the regions of overlap. Raw sequence data were
post-processed using the Mercury pipeline [18]. The
Mercury pipeline performs conversion of raw sequen-
cing data (bcl files) to a fastq format using Casava,
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erence sequence (GRCh37) using the Burrows-Wheeler
Alignment (BWA), recalibration using GATK [19], and
variant calling using the Atlas2 suite [20]. Finally,
Cassandra [21] was used to annotate relevant informa-
tion about gene names, predicted variant pathogenicity,
reference allele frequencies and metadata from external
resources, and then to add these to the Variant Call
Format (VCF) file.
After initial data processing every sample was evalu-
ated using rigorous QC metrics, including percentage of
targets covered at 20× or greater and concordance of
single nucleotide polymorphisms (SNPs) calls between
exome sequencing and SNP array data. Additionally,
each SNP variant call was filtered using the following
criteria: low single nucleotide variant (SNV) posterior
probability (<0.95), strand-bias of more than 99 % vari-
ant reads in a single strand direction and total coverage
less than tenfold. Moreover, sample level QC for ARIC
cohort removed known and blind duplicates, samples
with known sex mismatches (indicating sample contam-
ination), samples with missing rate >65 % and extreme
outliers (e.g., singleton counts). Only samples that
passed QC were included in this analysis.
Variants filtering
From the variants obtained by exome sequencing, we se-
lected nonsynonymous variants in a prespecified list of
56 SF genes or 1423 autosomal recessive disorder genes.
Additionally, for the analysis of females, we selected
nonsynonymous variants in an additional set of 112 X-
linked recessive genes. The list of SF genes was obtained
from the ACMG recommendations for reporting of sec-
ondary findings in clinical exomes [8], and includes 56
genes associated with 24 conditions, most of which are
inherited dominantly. The list of autosomal recessive
genes was created based on an extensive search of the
MedGen database [22], for all autosomal recessive disor-
ders (see Additional file 2 for details of gene extraction
procedure). The initial set of 1496 genes obtained from
MedGen was compared with the lists of autosomal
recessive disease genes described in previous studies
[23, 24] (Additional file 3). Next, we manually evalu-
ated Online Mendelian Inheritance in Man (OMIM)
entries for 314 MedGen genes not reported in the
previous studies to confirm that these genes are truly
associated with the autosomal recessive disorders. We
were able to identify a corresponding OMIM entry for
each of the 314 genes. Of those, we excluded 72 genes in
which we did not find evidence of homozygous or com-
pound heterozygous variants causing Mendelian disease.
We excluded TTN, which is the most commonly mutated
gene and could have an exaggerated influence on these
results. We present the list of genes at each filtering stepin Additional file 4. The final list of 1423 genes associated
with 1493 disorders is presented in Additional file 5.
Similarly, the list of 112 genes associated with 159 X-
linked recessive disorders (Additional file 6) was obtained
using the MedGen database and then manually curated.
Since the number of genes was significantly smaller than
in the case of autosomal recessive disease genes, we eval-
uated all of these genes in OMIM without comparing
them with the lists from previous studies. From the ori-
ginal list of the 126 genes extracted from MedGen, we
excluded genes for which we did not find evidence that a
hemizygous variant in a male is associated with a
Mendelian condition (Additional file 7).
To establish an upper bound for the frequency of
potential secondary findings, we considered the list
of stop-gain (nonsense), stop-loss and missense vari-
ants predicted to be deleterious by the RadialSVM
algorithm [11, 25]. We excluded variants with minor
allele frequency (MAF) >1 % in control databases (Exome
Sequencing Project [ESP] and 1000 Genomes) or with
MAF >2 % in our cohort and variants of low quality, i.e.,
with depth of coverage <20 and/or with the ratio of vari-
ant reads to total reads <0.2. The list of predicted dele-
terious variants was determined using the RadialSVM
score provided in dbNSFP v.2.5 [11, 25]. This support
vector machine (SVM)-based ensemble prediction score
incorporates ten other scores (SIFT, PolyPhen-2 HDIV,
PolyPhen-2 HVAR, GERP++, MutationTaster, Mutation
Assessor, FATHMM, LRT, SiPhy, PhyloP) and the max-
imum allele frequency observed in the 1000 Genomes
populations [11]. In comparison studies [26], this method
was shown to outperform other prediction algorithms
with the highest Mathews correlation coefficient (0.474)
and relatively low false negative rate (5 %) and false posi-
tive rate (57 %). RadialSVM was applied to all rare vari-
ants regardless of their classification in HGMD or
ClinVar. We removed nonsense variants that are located
in the last exon or in the last 50 bp of the penultimate
exon, which are likely to escape nonsense-mediated
decay (NMD) and thus they may be less damaging [27].
Reported pathogenic variants were obtained from the
ClinVar [10] and HGMD (Professional version 2012.4)
[28] databases. In this analysis, we considered a HGMD
variant as reported pathogenic if it was annotated as
“Disease-causing Mutation” (DM).
The ClinVar data used in this analysis were extracted
from the “clinvar-latest.vcf” file generated on 4 June
2014. Variants in ClinVar are reported by single or
multiple submitters, which may result in discordant
classifications. In this study, we defined a variant as
“pathogenic” if: (i) no submitter reported this variant
as “benign” or “likely benign”; and (ii) at least one
submitter classified this variant as “pathogenic”. We did
not include variants classified as “likely pathogenic” unless
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not use the recently implemented star rating in this
analysis.
Number of ClinVar submissions for different ethnic groups
We performed a comparison of the number of ClinVar
submission entries among four populations, including
Europeans, Africans, Hispanics and Asians (see Additional
file 2 for details).
Results
After QC, 8554 exomes were available from the ARIC
cohort and 2514 exomes were available from the CMG.
The average coverage was 92× and 105×, respectively.
We calculated coverage for the genes considered in this
analysis and the average percentage of bases with cover-
age of 20× or greater was 95 % for both ARIC and
CMG. ARIC included 5718 and 2836 self-reported EAs
and AAs, respectively. The average numbers of variants
per individual with a MAF <5 % were 1765 and 3870 for
ARIC EAs and AAs, respectively. The CMG sample set is
more ethnically heterogeneous resulting from the overall
objective of the program and the global nature of their as-
certainment. Additional file 8 shows the distributions of
the first two principal components relative to HapMap
comparison groups. A pie diagram of the assigned ethnic
group and study (ARIC or CMG) is presented as Fig. 1.Fig. 1 Assigned ethnicity by study origin for 8554 ARIC and 2514 CMG indReported pathogenic variants in SF genes
In the 11,068 exomes from ARIC and the CMG, 6221
unique nonsynonymous variants in the 56 ACMG SF
genes had a MAF of less than 1 %, and these variants
occurred 23,892 times across the study sample. The
number of SF gene variants in an individual ranged from
0–11, with an average of 2.2 (median of 2) variants per
individual. In 1550 individuals (~14 %), there were no
nonsynonymous variants in any of the a priori identified
SF genes, and six individuals had 10 or 11 such variants
(Fig. 2). More than half of the variants (3831 out of
6221) were observed only once and, of those, 3091 vari-
ants were absent in the 1000 Genomes and ESP data-
bases. Out of the 6221 nonsynonymous variants, we
identified 2815 predicted deleterious variants occurring
8167 times. These variants were found in 51 % of
individuals (5674 out of 11,068) with an average of 0.74
(median 1) predicted deleterious variants in the SF genes
per individual (Fig. 2).
In the 56 ACMG SF genes, we observed 642 occur-
rences of 136 unique variants reported in ClinVar as
pathogenic. These variants were present in 5.6 % of
study samples (623 out of 11,068 individuals); 19 indi-
viduals had more than one ClinVar reported pathogenic
variant (Fig. 3). Considering the HGMD-Disease-causing
Mutation (HGMD-DM) categorization, approximately
10 % of all unique variants (645 out of 6221) wereividuals
Fig. 2 Distribution of the number of annotated variants per individual in 56 ACMG SF genes. a Rare nonsynonymous variants. b Predicted
deleterious variants
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HGMD-DM variants showed that 35 % of individuals
(3871 out of 11,068) have at least one DM variant and of
those 847 have two or more (Fig. 3).
Nonsense variants in SF genes were found in 2 % of
the study sample (243 out of 11,068). Out of 76 unique
nonsense variants, 13 were reported as pathogenic by
both ClinVar and HGMD; one variant was reported only
by ClinVar and 18 only by HGMD. We detected 40
novel nonsense variants (53 % of all nonsense variants)
in the SF genes not classified in ClinVar or HGMD.
After excluding variants located in NMD-escaping regions,we observed 30 (32 occurrences) rare nonsense variants in
the SF genes that are likely to be pathogenic.
Carrier detection
We identified 111,049 rare nonsynonymous variants in
the a priori defined list of 1423 autosomal recessive dis-
ease genes. The frequency distribution of the number of
autosomal recessive disease variants per individual is
shown in Fig. 4 and appears bimodal, which reflects dif-
ferences among ethnic groups, with EAs having lower
numbers and AAs having higher numbers. After exclud-
ing non-deleterious variants, we observed 32,213 unique
Fig. 3 Distribution of the number of reported pathogenic variants per individual in 56 ACMG SF genes according to HGMD-DM (black bars),
ClinVar (light gray bars) and combined (dark gray bars) databases
Gambin et al. Genome Medicine  (2015) 7:54 Page 6 of 14deleterious variants occurring 105,323 times. Individuals
carried from 0–25 autosomal recessive disease variants
with an average of ten (median nine), and one individual
carried zero (Fig. 4). The majority of all variants (20,028
out of 32,213) were observed only once, and 16,106 of
these were not reported in 1000 Genomes and ESP
databases.
There were 1366 reported pathogenic ClinVar variants
observed in the list of 1423 autosomal recessive disease
genes, and these occurred 8634 times in the study
sample. Fifty-three percent of individuals in the sam-
ple (5858 out of 11,068) carry at least one reported
pathogenic ClinVar variant with an average of 0.78
(median = 1) variants per individual. Significantly more
unique reported pathogenic variants (4435) were identi-
fied using HGMD-DM, and 95 % of the individuals
(10,531 out of 11,068) contain at least one HGMD-DM
variant in an autosomal recessive gene. The number of
HGMD-DM variants in an individual ranged from 0 to
13 with an average of 3.2 (median of 3) per individ-
ual (Fig. 5). The majority of reported pathogenic
ClinVar variants (1261 out of 1366) had a concordant
annotation in HGMD. For these autosomal recessive
genes, we also observed significantly higher MAFs of
HGMD-DM variants (average MAF = 0.23 %; median
MAF = 0.19 %) in comparison with the ClinVar vari-
ants (average MAF = 0.21 %; median MAF = 0.13 %)
(Wilcoxon rank sum test, p value = 4.2e-33).
We found that 40 % of individuals (4164 out of 11,068)
carry a nonsense variant in one of the autosomal recessive
disease genes. From the total number of 2737 nonsense
variants (5295 occurrences, average MAF = 0.06 %), 478
(1139 occurrences, average MAF= 0.09 %) were found inNMD-escaping regions, further supporting previous ob-
servations of a significantly higher average nonsense
frequency in NMD-escaping regions than in other re-
gions of a gene where they are expected to reduce gene
expression [29, 30]. Approximately 10 % of nonsense
variants in autosomal recessive genes (265 out of 2737)
were reported as pathogenic by ClinVar and HGMD.
Additionally, 393 variants were reported as pathogenic
by only one of these databases (15 by ClinVar and 378
by HGMD). Seventy-five percent of the nonsense vari-
ants (2059 out of 2737) were not found in the 1000
Genomes and ESP databases. Out of those, 1667 (from
2705 occurrences) were located outside presumed
NMD-escaping regions. These novel nonsense variants
were identified in 22 % of all individuals (2380 out
of 11,068).
Percentage of couples at risk of having affected offspring
To estimate the percentage of couples in the general
population in which both partners have a reported
pathogenic variant in the same autosomal recessive dis-
ease gene, we performed the following resampling ex-
periment using data from the ARIC study. From this
random sample of individuals, which is likely representa-
tive of EA and AA couples planning to have children, we
randomly sampled two exomes (one from a male and
one from a female) to evaluate if they share at least one
autosomal recessive disease gene with a reported patho-
genic ClinVar variant. After 1,000,000 iterations, we ob-
served that 0.5 % of couples are at risk of having an
affected offspring. When this experiment was repeated
using predicted deleterious variants in the same list of
genes, the proportion of at-risk couples was 17.6 %,
Fig. 4 Distribution of the number of variants per individual in autosomal recessive disease genes. a Rare nonsynonymous variants. b Predicted
deleterious variants
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itionally, we calculated that 5 % of females (241 out of
4817) are carriers of a ClinVar reported pathogenic vari-
ant in an X-linked recessive disease gene. A predicted
deleterious variant in at least one X-linked disease gene
was found in 33 % of females (1587 out of 4817).
Comparison among ethnic groups
To compare the total burden of alleles in the SF and
autosomal recessive genes among five ethnic groups in-
cluded in this study, we determined the average number
of variants per individual and the fraction of individuals
carrying at least one variant for each ethnic group(Table 1). AAs carry, on average, around three nonsy-
nonymous variants in SF genes, and at least one SF
variant was identified in 96 % of all AAs, whereas indi-
viduals from the other groups contain significantly
fewer (Fig. 6). The fewest numbers of variants were
found in individuals of European descent, where we ob-
served that ~20 % of individuals do not have any non-
synonymous variants in SF genes. We did not observe
significant differences in the number of reported patho-
genic variants in ClinVar/HGMD among ethnic groups.
Except in individuals of Asian descent where the sample
size was small, 5–6 % of individuals in each group were
carriers for at least one reported pathogenic variant
Fig. 5 Distribution of the number of reported pathogenic variants per individual in autosomal recessive disease genes according to HGMD-DM
(black bars), ClinVar (light gray bars), and combined (dark gray bars) databases
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HGMD-DM variant.
Analysis of autosomal recessive genes showed that, on
average, individuals of European ancestry carry from
32–35 nonsynonymous variants, whereas individuals of
Hispanic (46), Turkish (46), Asian (57) and African des-





Number of samples 5718 1455
Average number of nonsynonymous
variants per individual
1.683 1.878
Fraction of individuals with nonsynonymous
variants
0.807 0.84
Average number of predicted deleterious
variants per individual
0.612 0.737
Fraction of individuals with predicted
deleterious variants
0.449 0.529
Average number of ClinVar variants
per individual
0.06 0.049
Fraction of individuals with ClinVar variants 0.058 0.048
Average number of HGMD variants
per individual
0.416 0.463
Fraction of individuals with HGMD-DM
variants
0.335 0.355
Average number of nonsense variants
per individual
0.007 0.006
Fraction of individuals with nonsense variants 0.007 0.006
These frequencies are reported for: 1) all rare nonsynonymous variants, 2) predicted
variants, 5) nonsense variantswas observed for deleterious variants, but the relative
differences among populations are slightly smaller. In
contrast, the highest average number of reported patho-
genic ClinVar variants was found in the European des-
cent population (0.88–0.92), whereas the average in the
African descent population was significantly smaller













2836 122 498 388 51
3.159 2.852 2.271 2.472 2.667
0.955 0.959 0.896 0.93 0.922
0.963 0.779 0.865 0.765 0.843
0.615 0.549 0.578 0.539 0.569
0.06 0.057 0.056 0.044 0.137
0.058 0.057 0.052 0.044 0.137
0.485 0.459 0.4 0.428 0.412
0.38 0.393 0.333 0.34 0.353
0.013 0.008 0.008 0.003 0
0.013 0.008 0.008 0.003 0
deleterious variants, 3) reported pathogenic ClinVar variants, 4) HGMD-DM
Fig. 6 Distributions of the number of annotated nonsynonymous variants among ethnic groups in 56 ACMG SF genes (a) and in autosomal
recessive disease genes (b)
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Similarly, the average number of HGMD-DM variants in
individuals of European descent (3.44–3.59) was ~50 %
higher than the average in those of African descent
(2.23–2.35). Individuals with Turkish ancestry had the
highest carrier frequency of HGMD-DM autosomal
recessive alleles (3.85).
Population diversity in ClinVar
A comparison of the number of ClinVar entries among
different populations revealed apparent enrichment of
variants submitted for European individuals (12,918 outof 36,933 records; Additional file 9). Asians (11,712
records) and Africans (6148 records) are underrepre-
sented in ClinVar, especially if one takes into account
the size of the populations in comparison to Europeans.
Discussion
We sequenced the exomes of 11,068 individuals from a
large biracial cohort study and from a study of presumed
Mendelian disease that includes individuals from five
ethnic groups, and analyzed the frequency of SFs and
assessed the autosomal recessive disease allele carrier
status. In the 56 ACMG SF genes, the average number















Number of samples 5718 1455 2836 122 498 388 51
Average number of nonsynonymous variants
per individual
32.332 35.135 60.265 56.156 46.177 45.943 57.176
Fraction of individuals with nonsynonymous variants 1 1 1 1 1 1 1
Average number of predicted deleterious variants
per individual
8.132 8.792 12.187 11.984 10.871 10.369 11.176
Fraction of individuals with predicted deleterious variants 1 1 1 1 1 1 1
Average number of ClinVar variants per individual 0.883 0.919 0.527 0.492 0.801 0.675 0.627
Fraction of individuals with ClinVar variants 0.583 0.601 0.397 0.369 0.538 0.487 0.431
Average number of HGMD variants per individual 3.44 3.59 2.346 2.23 3.851 3.423 3.039
Fraction of individuals with HGMD-DM variants 0.965 0.977 0.904 0.926 0.978 0.969 1
Average number of nonsense variants per individuals 0.358 0.402 0.385 0.311 0.416 0.423 0.412
Fraction of individuals with nonsense variants 0.301 0.321 0.316 0.27 0.345 0.338 0.353
These frequencies are reported for: 1) all rare nonsynonymous variants, 2) predicted deleterious variants, 3) reported pathogenic ClinVar variants, 4) HGMD-DM
variants, 5) nonsense variants
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of individuals had at least one such variant. There were
642 occurrences of 136 unique SF variants reported in
the ClinVar database as pathogenic. There were 1366 re-
ported pathogenic ClinVar variants observed in the list
of 1423 autosomal recessive disease genes. We observed
32,213 unique deleterious variants in autosomal reces-
sive disease genes occurring 105,323 times, with an aver-
age of 10 such variants per individual. About one-half of
one percent of couples are at risk of having an affected
offspring for an autosomal recessive disorder based on
ClinVar variants reported as pathogenic. Surprisingly,
this number is 17.6 % if all observed predicted dele-
terious alleles in autosomal recessive disorder genes
are considered. This forms a likely upper bound for
the frequency of at-risk couples as many of these
presumed damaging variants may have no effect on
protein function or disease risk, emphasizing the fu-
ture value of experimentally evaluating their potential
functional consequences and elucidating their real
pathogenicity.
An informative comparison of the SFs observed here
with the frequencies reported from previous studies is
challenging because the list of genes, variant classifica-
tion databases and interpretation of clinical significance
are evolving. For example, Johnston et al. [31] screened
variants in 37 cancer-susceptibility genes, but only 23 of
these genes were included in the ACMG list. Berg et al.
[32] studied SFs in 2016 genes categorized into “bins”
based on clinical utility and validity. One of these bins
includes 161 clinically actionable genes, from which 31
genes were used in our study. Dorschner et al. [9]
analyzed 114 genes, including 52 from the ACMGrecommendation. Despite these differences, it is possible
to identify emerging trends.
It is known that individuals of African descent have
more nonsynonymous SNVs than individuals from other
populations [33] so that one would expect an enrich-
ment of reported pathogenic variants in this group. In
fact, we found that the average number of nonsense vari-
ants in AAs (0.013) is significantly higher than in EAs
(0.007). The analysis of predicted deleterious variants
further supports this finding. Similarly, Dorschner et al.
[9], who analyzed 500 EAs and 500 AAs, noted that out
of five novel likely pathogenic nonsense variants, three
were found in AAs. On the other hand, we observe the
opposite trend when only previously reported patho-
genic variants are considered. For example, the average
number of reported pathogenic ClinVar variants in auto-
somal recessive disease-causing genes is 0.53 in AAs and
0.88 in EAs. Consistent with our observation of the
striking deficit of pathogenic variants in AAs, Dorschner
et al. [9] reported that only 3 out of 18 pathogenic or
likely pathogenic variants were present in individuals of
African descent. It was postulated that the most likely
explanation for this finding is the underrepresentation of
African descent individuals in the clinical genetics litera-
ture [9]. Although other hypotheses, such as a European
bottleneck, were previously considered to explain the in-
creased number of deleterious variants in Europeans
[34], recent studies show no evidence of a higher load of
deleterious variants in non-African populations [35]. In
this study, we explore the frequency of SF variants in
Turkish, Hispanic and Asian populations. In general, we
observed that the frequencies of both reported patho-
genic and predicted deleterious variants are between the
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African descent populations.
As previously noted [31], large scale manual curation
of variants in the era of massive whole exome or whole
genome sequencing to identify clinical pathogenicity is
not practical. Therefore, automation of curated data-
bases containing pathogenic variants and better predic-
tion algorithms are each necessary. In addition to the
number of HGMD-DM variants, our study reports the
frequencies of reported pathogenic variants derived from
the ClinVar database. The number of pathogenic vari-
ants reported in ClinVar is one-sixth of the number in
HGMD-DM [36], and 136 SF ClinVar and 645 SF
HGMD-DM variants were identified in this study. Our
estimate of the reported pathogenic variant frequency in
SF genes (5.6 %) based on ClinVar is slightly higher than
the frequencies reported by Dorschner et al. [9] (1.2–
3.4 %), who performed additional manual curation. On
the other hand, our estimate was based on the annota-
tions provided in ClinVar, which established more
conservative and transparent inclusion criteria for patho-
genic variants. Although no database is error-free, well-
structured repositories not only provide an opportunity
to streamline variant filtering and automate the first pass
analysis, but also help avoid error-prone subjective deci-
sions intrinsically introduced by manual curation.
In this study, 2171 annotated predicted deleterious
nonsynonymous variants in SF genes were not present
in either ClinVar or HGMD, and these variants have a
significantly lower allele frequency than the variants
found in those data resources (Additional file 10). The
high frequency of HGMD/ClinVar variants is most likely
because they have already been seen in other studies,
which increases the prior probability of observing this
variant again in a sample from the general population.
Having a low MAF is a predictor of variant pathogen-
icity [37] and a fraction of these rare unclassified vari-
ants are likely to be pathogenic. In the case of nonsense
variants in SF genes, this fraction can be as high as 39 %
based on the observation that 30 out of 76 likely patho-
genic nonsense variants in SF genes were not reported
in HGMD or ClinVar.
Although reported pathogenic ClinVar variants and
novel nonsense variants were found in only a small per-
centage of individuals, we observed that about half of
the individuals in our sample (5674 out of 11,068) have
a predicted deleterious nonsynonymous variant in at
least one SF gene. We anticipate that with the acceler-
ated pace of gene and pathogenic variant discovery and
the growth of commercial clinical sequencing programs
[2], the number of ClinVar variants and the amount of
additional data evaluating the level of clinical signifi-
cance of previously reported variants will greatly in-
crease, which will further improve the quality of variantclassification. We also observed that African and Asian
populations are underrepresented in the ClinVar data-
base (Additional file 9). Therefore, a larger number of
submissions from ethnicities other than Europeans will
enable more accurate comparison of the burden of
pathogenic variants among different populations.
There is growing interest among the public regarding
carrier detection for autosomal recessive conditions.
Carrier testing is no longer limited to specific ethnic
groups having a high frequency of certain conditions or
extended families aggregating for a specific condition.
Surveys indicate that more than two-thirds of people
would like to have their genome sequenced [38]. As the
cost of sequencing continues to decline and the ability
to interpret the sequence information with respect to
health and disease improves, the frequency is likely to
continue to increase. Sequence-based carrier tests fall
into two subtypes: targeted sequencing of known disease
genes and exome or whole genome sequencing. Targeted
sequencing lacks the ability to rapidly incorporate newly
reported disease genes. In a recent study, 30 % of whole
exome-based diagnoses were in genes reported since
2011 [2]. The second category of test holds the most
promise because of its comprehensive nature, but suffers
from its relatively high cost and the need to catalogue
and update potentially large numbers of variants of un-
known significance. Formal cost-benefit analyses of these
options are limited [39–42], and further studies are
needed in this growing molecular diagnostic area.
We estimated that a minimum of 0.5 % of randomly
paired individuals are at 1 in 4 risk of having an off-
spring affected by alleles in a known recessive disease
gene. When all predicted deleterious variants are consid-
ered, we observed that the fraction of couples being at
risk can be as high as 17.6 %. The global prevalence of
all monogenic diseases is estimated to be ~10/1000 [43]
and autosomal recessive (AR) diseases account for one-
third of them [44], implying that frequency of AR dis-
ease is ~3/1000. This further suggests that the expected
fraction of couples at risk for having an offspring with
an AR disorder is ~1.2 % (4 × 3/1000), a value much
smaller than 17.6 %. The difference is likely attributable
to small effect sizes, incomplete penetrance, subclinical
manifestations of Mendelian diseases, or Mendelian
forms of common diseases. Similarly, we estimated the
percentage of females carrying a reported pathogenic
ClinVar variant in X-linked disease genes to be 5 % and
those having predicted deleterious variants in the same
list of genes to be 33 %. As the number of gene discover-
ies continues to increase, these proportions will also
increase. A comparison of the numbers derived from re-
ported pathogenic variants and the numbers calculated
based on predicted deleterious variants (i.e., 0.5 % versus
17.6 % or 5 % versus 33 %) reflects the lower and upper
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pathogenic variants should be evaluated more carefully.
While reported pathogenic variants are likely to be in-
cluded in the primary report of a carrier test, additional
deleterious variants of unknown significance can be also
considered if additional data are present (e.g., family
history) and reevaluated when new information becomes
available.
The burden of recessive carrier status has been previ-
ously investigated [23, 24, 32, 45, 46]. Lazarin et al. [45]
used targeted genotyping and showed that 24 % of individ-
uals are carriers for selected, previously reported recessive
alleles in 108 genes. Bell et al. [23] sequenced 437 pediatric
recessive disorder genes and obtained somewhat higher
estimates (2.8 variants per individual) than that of Lazarin
et al. [45]. In our study, we report the average number of
variants in 1423 autosomal recessive disease genes to be at
least as high as that reported by Bell et al. [23]. We ob-
served that each individual in our study sample is a carrier,
on average, of 0.78 reported ClinVar pathogenic variants.
Although the false positive rate of available prediction
software is still far from excellence (estimated false posi-
tive rate of RadialSVM is ~57 % [26]), the average value of
ten predicted deleterious variants per individual is a rea-
sonable approximation of the upper limit for the total
burden of autosomal recessive carrier status.
Conclusions
SFs were ascertained in AAs, EAs and five additional
populations. Considering the list of 56 SF genes, the ex-
pected number of reported pathogenic SFs in each newly
sequenced individual is small in comparison with the ex-
pected number of predicted deleterious variants. For ex-
ample, each individual in this study sample has a 1 in 18
(5.6 % of study sample) chance of possessing a previ-
ously reported ClinVar variant in one of the 56 ACMG
actionable genes. In contrast, when considering all cases
with reported pathogenic ClinVar variants, we found
that each individual has 1 in 2 risk (51 % of study
sample) of having a predicted deleterious nonsynon-
ymous variant in these same genes. Similarly, 0.5 % of
couples are at risk of having an affected offspring for an
autosomal recessive disorder based on ClinVar variants;
this number is 17.6 % considering all observed predicted
deleterious alleles in autosomal recessive disorder genes.
These data define the upper and lower bound of the fre-
quency of SF findings and carrier detection results. We
observed ethnic differences in the frequency of second-
ary findings and autosomal recessive carrier frequencies.
AAs carry, on average, around three nonsynonymous
variants in the SF genes, whereas EAs have around two.
For carriers of autosomal recessive disease alleles, indi-
viduals of European ancestry had the lowest carrier fre-
quency, while individuals of African ancestry had thehighest. The highest average number of reported patho-
genic variants was found in the European population,
but this likely reflects a reporting bias caused by the higher
volume of submissions for this widely studied ethnic group
(Additional file 9). Clearly, more discovery efforts are
needed in non-European ancestry populations.
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Additional file 1: List of phenotypes in the CMG cohort.
Additional file 2: Describes the procedure of recessive disease gene
extraction from MedGen and the procedure we used to compare
the number of ClinVar submission for different ethnic groups.
Additional file 3: Venn diagram showing the comparison of the list
of autosomal recessive genes generated based on MedGen query
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Bell et al. [23].
Additional file 4: The first column of Additional file 4 includes the
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associated with autosomal recessive disorders. The second and third
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and the fourth column presents the genes selected for manual curation. The
fifth column shows the results of the final selection, i.e., genes overlapping
with previous studies or those that passed manual curation.
Additional file 5: The final list of autosomal recessive genes and
conditions obtained from the MedGen database. It does not include
genes that were excluded in the manual curation step (see Methods).
Additional file 6: The final list of X-linked recessive genes and
conditions obtained from the MedGen database. It does not
include genes that were excluded in the manual curation step (see
Methods).
Additional file 7: The first column of Additional file 7 includes the
original list of genes extracted from MedGen that are potentially
associated with X-linked recessive disorders. The second column
indicates genes that passed manual curation.
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principal components relative to a HapMap comparison group for
individuals from the CMG cohort.
Additional file 9: Shows the number of ClinVar submissions for
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Additional file 10: Shows differences in MAF between reported
pathogenic variants and those not classified in HGMD or ClinVar
but predicted to be deleterious in the SF genes (a) or in autosomal
recessive disease genes (b).
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